Evidence map›Paper›PMID 40825105›Full record

ArticleThe Prostate2025

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes.

Christian P Pavlovich, Jun Wei, Marta Gielzak, Zhuqing Shi, Huy Tran, Annabelle Ashworth, S Lilly Zheng, Patrick C Walsh, Jun Luo, Brian T Helfand and 2 more

Abstract read
In one paragraph

Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christian P PavlovichJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jun WeiProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
Marta GielzakJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Zhuqing ShiProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
Huy TranProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
Annabelle AshworthProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
S Lilly ZhengProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
Patrick C WalshJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jun LuoJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Brian T HelfandProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.
William B IsaacsJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jianfeng XuProgram for Genomic Translational Research, Endeavor Health, Evanston, Illinois, USA.ORCID 0000-0002-1343-8752

Funding

Patrick C Walsh Hereditary Prostate Cancer Program and the Ambrose Monell Foundation.
6 · The paper itself

Abstract

backgroundTo independently assess data for recently reported genes-BIK, SAMHD1, FAM111A, and AOX1-in which rare variants have been associated with prostate cancer (PCa) risk and aggressiveness.

methodsThe study included 4448 PCa cases from Johns Hopkins School of Medicine and 103,221 population-based controls from the Genome Aggregation Database (gnomAD). Gene-based and variant-based association tests were performed within each major ancestry group using Fisher's exact test and Firth logistic regression. Bonferroni-corrected significance thresholds were applied to account for multiple testing. RESULTS AND

conclusionIn the NFE population, suggestive statistical evidence of association with PCa risk was found for two of the four genes, BIK and SAMHD1. The evidence was primarily driven by missense variants: BIK S87G and SAMHD1 Q465K and V112I. The effect sizes of these variants were stronger than, or comparable to, those of well-established PCa risk variants such as HOXB13 G84E and CHEK2 T367fs. A weak association signal was observed between AOX1 and PCa aggressiveness. Statistical power was limited for analyses in other ancestry groups, particularly for tests of PCa aggressiveness. Implication of BIK and SAMHD1 as PCa susceptibility genes represents a major breakthrough since the discovery of HOXB13 in 2012 and may have clinical utility for risk stratification and contribute to our understanding of the molecular etiology of PCa.

Indexed as

Genetic Predisposition to DiseaseMitochondrial ProteinsProstatic NeoplasmsSAM Domain and HD Domain-Containing Protein 1AgedCase-Control StudiesHumansMaleMiddle AgedMitochondrial ProteinsSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanAOX1BIKFAM111Agermlinemutationprostate cancerSAMHD1

Identifiers

PMID40825105
PMCPMC12603878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.